Get started
ALGERNON PHARMACEUTICALS INC.ALGERNON PHARMACEUTICALS INC.ALGERNON PHARMACEUTICALS INC.

ALGERNON PHARMACEUTICALS INC.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

AGN trade ideas

Is the Nike swoosh a chart pattern you can trade off? Hey All, take a look at the chart pattern on AGN, seems to be really consistent, swoosh, then crash then consolidate, swoosh then crash then consolidate. Have i been looking at too many charts? Seeing things? lol, its a possibility, but it looks to me like we are starting a swoosh down right now after coming off highs at AGN. Either that or we are about to spike, then resume the "swoosh" pattern... lol Let me know your thoughts!
CSE:AGN
by Dirtweed
AGN Long, but caution!Another stock getting some attention during COVD. These guys have a good model, basically standing on the shoulders of others and reworking their formulas to make their own Vaccines. There is potential for this company post covid, provided they get a vaccine going. I took a small stake in this company based on Pre Covid activities. IF they do end up getting a vaccine going, imagine the spike it could see. Mere mention of it made it increase large, I don't even need to draw any trendlines here. This one is kind of a gamble right now, but the rewards could be massive! Short term, i'd say there is some upside potential, but we need to beat others to the punch and get a vaccine out soon. CSE:AGN
CSE:AGNLong
by Dirtweed
2
AGN.C -- Coronavirus Treatment Spec; Phase 2 Clinical Trial newsAnother CoronaVirus spec play. Pulled back from recent highs and trading in the support band, for now. I bought in at .20 - .21 today. $18M mkt cap. 90M float. Could see a nice run on today's news: Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Novotech, a leading Asia-Pacific clinical research organization (CRO), has identified physicians in South Korea who have agreed to conduct an investigator initiated phase 2 clinical trial of Ifenprodil for coronavirus patients. The investigators were identified after Algernon retained Novotech to conduct a feasibility study in South Korea. Novotech was asked to advise on the most efficient regulatory approach to initiating a phase 2 clinical trial for Ifenprodil for COVID-19 and to also help identify potential investigators. Ifenprodil is an already approved drug in South Korea and Japan for certain neurological conditions with a known safety history. Algernon has been investigating Ifenprodil under its re-purposed drug program and has appointed Novotech as the lead CRO for its upcoming idiopathic pulmonary fibrosis (IPF) and chronic cough phase 2 clinical trial to be conducted in Australia. The Company is in the process of refining the protocol for the phase 2 coronavirus study after receiving input from the investigators, and is working with Novotech to provide the necessary information and support in order to assist with the study’s approval. The study approval process may be expedited due to the current global health crisis. The Company will release more information about the planned phase 2 coronavirus study shortly. The decision to retain Novotech to conduct a feasibility study was made after a recent independent study found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. The drug was also previously shown in a separate study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function. “This independent study data, along with the data generated from the Company’s animal studies on IPF and chronic cough, have supported the Company’s recent new COVID-19 and acute lung injury clinical program,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
CSE:AGNLong
by wealth_bakery